Intra-Cellular Therapies Inc (NASDAQ: ITCI) on Monday, plunged -0.11% from the previous trading day, before settling in for the closing price of $127.35. Within the past 52 weeks, ITCI’s price has moved between $62.78 and $128.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 9522.17% annually for the last half of the decade. The company achieved an average annual earnings per share of 57.40%. With a float of $99.30 million, this company’s outstanding shares have now reached $106.00 million.
In an organization with 610 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 92.29%, operating margin of -19.84%, and the pretax margin is -13.89%.
Intra-Cellular Therapies Inc (ITCI) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Intra-Cellular Therapies Inc is 6.53%, while institutional ownership is 90.35%. The most recent insider transaction that took place on Dec 04 ’24, was worth 4,375,659. In this transaction Chairman and CEO of this company sold 51,000 shares at a rate of $85.80, taking the stock ownership to the 1,070,329 shares. Before that another transaction happened on Dec 05 ’24, when Company’s Chairman and CEO sold 51,697 for $84.08, making the entire transaction worth $4,346,842. This insider now owns 1,070,329 shares in total.
Intra-Cellular Therapies Inc (ITCI) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 57.40% per share during the next fiscal year.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Trading Performance Indicators
Intra-Cellular Therapies Inc (ITCI) is currently performing well based on its current performance indicators. A quick ratio of 7.51 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.37 in one year’s time.
Technical Analysis of Intra-Cellular Therapies Inc (ITCI)
Let’s dig in a bit further. During the last 5-days, its volume was 4.9 million. That was inferior than the volume of 6.57 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 80.14%. Additionally, its Average True Range was 3.08.
During the past 100 days, Intra-Cellular Therapies Inc’s (ITCI) raw stochastic average was set at 98.62%, which indicates a significant increase from 98.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 128.51% in the past 14 days, which was higher than the 58.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $93.41, while its 200-day Moving Average is $78.72. However, in the short run, Intra-Cellular Therapies Inc’s stock first resistance to watch stands at $127.40. Second resistance stands at $127.59. The third major resistance level sits at $127.71. If the price goes on to break the first support level at $127.08, it is likely to go to the next support level at $126.96. The third support level lies at $126.77 if the price breaches the second support level.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Key Stats
Market capitalization of the company is 13.52 billion based on 106,017K outstanding shares. Right now, sales total 464,370 K and income totals -139,670 K. The company made 175,380 K in profit during its latest quarter, and -26,320 K in sales during its previous quarter.
